<DOC>
	<DOCNO>NCT02153112</DOCNO>
	<brief_summary>The purpose study select optimal formulation norovirus vaccine different concentration virus-like particle ( VLP ) combine aluminum hydroxide development child .</brief_summary>
	<brief_title>Safety Immunogenicity Norovirus GI.1/GII.4 Bivalent VLP Vaccine Children</brief_title>
	<detailed_description>The vaccine test study call norovirus GI.1/GII.4 bivalent virus-like particle ( VLP ) vaccine aluminum hydroxide . The norovirus vaccine test assess different formulation vaccine develop . This study look number antibody norovirus form child , toddler infant administer different formulation norovirus vaccine . The study enroll approximately 840 participant . Participants randomly assign ( chance ) one ten treatment groups—which remain undisclosed participant study doctor study ( unless urgent medical need ) . All participant Cohort 1 vaccinate Day 1 Day 29 study , participant Cohort 2 vaccinate Day 1 , Day 56 , Day 112 . All treatment group Cohort 1 receive either one dose norovirus vaccine , two dos . One treatment group Cohort 2 receive 2 dos norovirus vaccine , group receive 3 . In order keep treatment undisclosed participant doctor Cohort 1 , randomize one-dose group receive norovirus vaccine Day 1 , follow dose placebo vaccine Day 29 . In order keep treatment arm undisclosed participant doctor Cohort 2 , randomize two-dose group receive norovirus vaccine Day 1 Day 56 , follow dose placebo vaccine Day 112 . Placebo vaccine saline solution . Participants ask record symptom may relate vaccine injection site diary card 7 day vaccination . This multi-center trial conduct Finland , Panama , Colombia . The overall time participate study 210 day participant Cohort 1 293 Days participant Cohort 2 . Participants Cohort 1 make 6 visit clinic , participant Cohort 2 make 10 visit clinic .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>1 . Male female participant age 6 week less 9 year time enrollment . 2 . Are good health time entry trial determine medical history , physical examination ( include vital sign ) clinical judgment investigator . 3 . Participants legally authorize representative ( LAR ) sign date write , informed consent form ( ICF ) require privacy authorization prior initiation trial procedure , nature trial explain accord local regulatory requirement . An assent also obtain accord ageappropriate countryspecific regulation . 4 . Participants comply trial procedure available duration trial . 1 . Participants clinically significant active infection ( assessed investigator ) body temperature 38.0°C ( 100.4°F ) high within 3 day intend date vaccination . 2 . Have receive antipyretic/analgesic medication within 24 hour prior intend vaccine administration . 3 . Known hypersensitivity allergy investigational vaccine ( include excipients investigational vaccine ) . 4 . Participants behavioral cognitive impairment psychiatric disease , opinion investigator , may interfere ability participate trial . 5 . Has history progressive severe neurologic disorder , seizure disorder , neuroinflammatory disease ( eg , GuillainBarré syndrome ) . 6 . Known suspected impairment/alteration immune function , include follow : 1 . Children &lt; 18 month age history repeat episode acute otitis medium ( AOM ) first 6 month life ( AOM define bulge tympanic membrane ) confuse otitis medium effusion ( OME ) . 2 . Chronic use oral steroid ( equivalent 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day ≥2 week ) within 60 day prior Day 1 ( use inhale , intranasal , topical corticosteroid allow ) . 3 . Receipt parenteral steroid ( equivalent 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day ≥2 week ) within 60 day prior Day 1 . 4 . Receipt immunostimulants within 60 day prior Day 1 . 5 . Receipt parenteral , epidural , intraarticular immunoglobulin preparation , blood product , and/or plasma derivative within 3 month prior Day 1 plan full length trial . 6 . Receipt immunosuppressive therapy within 6 month prior Day 1 . 7 . Human immunodeficiency virus ( HIV ) infection HIVrelated disease . 8 . Chronic Hepatitis B C infection . 9 . Heritable immunodeficiency . 7 . Abnormalities splenic thymic function . 8 . Has know bleed diathesis condition may associate prolonged bleeding time . 9 . Has serious chronic progressive disease accord judgment investigator ( e.g. , neoplasm , insulin dependent diabetes , cardiac , renal , hepatic disease ) . 10 . Is participate clinical trial another investigational product 30 day prior first trial visit intent participate another clinical trial time conduct trial . 11 . Has receive vaccine within 14 day ( inactivated vaccine ) 28 day ( live vaccine ) prior enrollment trial . 12 . Are first degree relative individual involve trial conduct . 13 . Has history autoimmune disease .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>